Subscribe to our newsletter.
FMS-like tyrosine kinase 3 is a receptor that plays a crucial role in hematopoiesis, the formation of blood cells. Mutations in the FLT3 gene are commonly found in acute myeloid leukemia (AML) and are often associated with poor prognosis. These mutations lead to constitutive activation of the FLT3 receptor, promoting uncontrolled cell proliferation and survival. Understanding the FLT3 mutation status is vital for the management of AML and can guide the use of targeted therapies like FLT3 inhibitors. Testing for FLT3 mutations is thus an essential part of diagnostic and treatment strategies in hematological malignancies.